TherapeuticsMD Revenue, Profits - TXMD Annual Income Statement

Add to My Stocks
$6.22 $0.1 (1.63%) TXMD stock closing price Sep 19, 2018 (Closing)

Financial analysis of TherapeuticsMD involves more than just checking the TherapeuticsMD stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement for TXMD which shows a YOY revenue decline of -13.33% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The operating expenses as shown in the TherapeuticsMD profit and loss statement for 2017 total to $91.55M. This line item shows that the operating expenses has decreased compared with last year. Also check: TherapeuticsMD assets and TherapeuticsMD free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
TherapeuticsMD Revenues or Net Sales
16.77M19.35M20.14M15.02M8.77M3.81M2.08M
Cost Of Goods Sold (COGS)2.63M4.18M4.5M3.67M1.95M1.34M-
TherapeuticsMD Gross Profit
14.14M15.17M15.63M11.35M6.81M2.46M1.14M
Research & Development Expense33.85M53.94M72.04M43.21M13.55M4.49M-
Selling General & Admin Expense57.7M51.34M28.72M22.12M19.01M14.06M6.4M
Income Before Depreciation Depletion Amortization-77.41M-90.12M-85.12M-53.98M-25.75M-16.09M-5.37M
Depreciation Depletion Amortization-------
Non Operating Income----0.17M-1.44M-18.67M-7.45M
Interest Expense----1.16M--
TherapeuticsMD Pretax Income
-76.92M-89.87M-85.07M-54.21M-28.41M-35.12M-12.91M
Provision for Income Taxes-------
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-76.92M-89.87M-85.07M-54.21M-28.41M-35.12M-12.91M
Extraordinary Items & Discontinued Operations-------
TherapeuticsMD Profit/ Loss (Net Income)
-76.92M-89.87M-85.07M-54.21M-28.41M-35.12M-12.91M
Average Shares used to compute Diluted EPS205.52M196.09M173.17M149.73M127.57M91.63M-
Average Shares used to compute Basic EPS205.52M196.09M173.17M149.73M127.57M91.63M-
Income Before Nonrecurring Items-76.93M-89.88M-85.08M-54.22M-28.02M-24.81M-
Income from Nonrecurring Items-----0.4M-10.31M-
TherapeuticsMD Earnings Per Share Basic Net
-0.37-0.46-0.49-0.36-0.22-0.38-
TherapeuticsMD Earnings Per Share Diluted Net
-0.37-0.46-0.49-0.36-0.22-0.38-
EPS Diluted Before Nonrecurring Items-0.37-0.46-0.49-0.36-0.22-0.27-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on TherapeuticsMD stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: TherapeuticsMD revenue chart implies that the company is growing. It has not been the case with TherapeuticsMD. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. TXMD stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the TXMD income statement, one can check the TherapeuticsMD historical stock prices to check how the price has moved with time.

TherapeuticsMD Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
83.85
Dividend Yield
0%